Barry E. Greene
Board Member
Karyopharm Therapeutics Inc. (KPTI)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Barry E. Greene
Barry E. Greene is recorded as Board Member at Karyopharm Therapeutics Inc. (KPTI). Karyopharm Therapeutics Inc. reported in an 8-K filed May 28, 2026 that Barry E. Greene was appointed Class I director, effective May 21, 2026. Karyopharm Therapeutics Inc. reported in an 8-K filed May 25, 2023 that Barry E. Greene was appointed Class I director, effective May 24, 2023.
“The Company's stockholders elected Barry E. Greene and Christy J. Oliger as Class I directors, each to serve on the Board for a three-year term until the 2029 annual meeting of stockholders and until his or her resignation or removal or until his or her successor is duly elected and qualified.”
“The Company’s stockholders elected Barry E. Greene, Mansoor Raza Mirza M.D. and Christy J. Oliger as Class I directors, each to serve on the Board for a three-year term until the 2026 annual meeting of stockholders and until his or her resignation or removal or until his or her successor is duly elected and qualified.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Karyopharm Therapeutics Inc.
Other people whose current roles at this company are on record from its filings.
- Richard Paulson CEO, Board Member
- Senior Clinical CEO
- Michael Mano General Counsel
- Kristin Abate Chief Accounting Officer
- Chen Schor Board Member
- Christy J Oliger Board Member
- Christy J. Oliger Board Member
- Deepika R. Pakianathan Board Member
- Garen G. Bohlin Board Member
- Mansoor Raza Mirza M.D. Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.